Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial

Kiski, D.; Stepper, Wibke; Brand, Eva; Breithardt, Günter; Reinecke, Holger

doi:10.1093/ndt/gfp582

Cited by 55 publications

(52 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, a few studies concluded that taking RAAS blockers is an independent risk factor for AKI 18,19) . Considering the preventive effect of ACEI on the decline in renal function in patients with CKD in previous long-term follow-up studies in which patients were not treated with PCI 20,21) , ACEI might contribute to the prevention of renal dysfunction in the acute phase after PCI.…”

Section: Measurement Of Cysc For the Assessment Of Renal Functionmentioning

confidence: 99%

Angiotensin-Converting Enzyme Inhibitor Prevents the Worsening of Renal Function in the Late Phase after Percutaneous Coronary Intervention

Kanda

Takumi

Miyata

et al. 2016

JAT

View full text Add to dashboard Cite

Aim:The amount of contrast media and renal atheroemboli are risk factors for acute kidney injury after percutaneous coronary intervention (PCI). However, the chronic kidney injury after PCI has not been fully characterized. The purpose of this study was to investigate factors affecting renal function in the late phase after PCI by measuring serum Cystatin C (CysC). Methods: In 143 consecutive patients who underwent elective PCI, CysC was evaluated at baseline and at 9 months after PCI, and the percent change in CysC (%CysC) was calculated. The association between %CysC and baseline characteristics, including medication use, was assessed.

show abstract

Section: Measurement Of Cysc For the Assessment Of Renal Functionmentioning

confidence: 99%

Angiotensin-Converting Enzyme Inhibitor Prevents the Worsening of Renal Function in the Late Phase after Percutaneous Coronary Intervention

Kanda

Takumi

Miyata

et al. 2016

JAT

View full text Add to dashboard Cite

show abstract

“…This association was even stronger in ARB group compared to ACEI group. In a recent study, impact of ACEI and ARB on the frequency of CIN was evaluated through a post hoc analysis from the DVD trial (20). This study showed that patients receiving ACEI or ARB while undergoing cardiac catheterization significantly more often developed CIN within 72 h after coronary procedure.…”

Section: Discussionmentioning

confidence: 99%

The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients

Barış¹,

Özpelit²,

Doğan³

et al. 2012

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: There is conflicting data about the role of renin-angiotensin-aldosterone system (RAAS) blockers in contrast-induced nephropathy (CIN) pathophysiology. In this study, we aimed to investigate the effects of chronic usage of RAAS blocker drugs on development of CIN in low risk patients. Methods: Study was designed as a prospective cohort study. A total of 295 patients were enrolled in the study. Study population was consisted of three subgroups according to prior usage of RAAS blockers: no RAAS blocker group (n=95), angiotensin-converting enzyme inhibitor (ACEI) group (n=106), angiotensin receptor blocker (ARB) group (n=94). CIN was defined as an increase of ≥25% in creatinine over the baseline value or 0.5 mg/dL rise within 48-72 h of angiography. Mehran score was calculated for each patient. Baseline variables and percentage of CIN were compared with ANOVA, Mann-Whitney U, Kruskal-Wallis and Pearson Chi-square tests between groups. In order to determine the independent predictors of CIN, binary logistic regression analyses were performed. Results: CIN occurred in 18 patients (17.0%) in the ACEI group, 17 patients (18.1%) in ARB group and 7 patients (7.4%) in the no RAAS group. CIN occurrence was significantly higher in RAAS than no RAAS group (17.5% vs. 7.4%, p=0.01). Chronic RAAS blocker administration was an independent predictor of CIN (OR=2.69; 95% CI: 1.025-7.067; p=0.04). Mehran score was the only other independent predictor for CIN (OR=1.15; 95% CI: 1.019-1.310; p=0.02).

show abstract

“…CIN developed 11.9% in ACE-inhibitor using group and 4.2% in control group (p=0.006). Use of ARB or ACE inhibitors was found as a risk for CIN (OR=3.08, p=0.016) (Kiski et al, 2010). Checking the use of ACE inhibitors or ARB before coronary angiography seems to be a useful guide in tracking risk assessment for CIN.…”

Section: Ace Inhibitors and Angiotensin Receptor Blockersmentioning

confidence: 97%

Coronary Angiography and Contrast-Induced Nephropathy

Toprak¹

2011

Advances in the Diagnosis of Coronary Atherosclerosis

View full text Add to dashboard Cite

Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial

Abstract: Patients treated with RAAS blockade before exposure to CM develop significantly more often CIN within 72 h. Even after adjustment for confounding comorbidities, treatment with ACE-I or AT-1 blockers turned out to be an independent risk predictor.

Cited by 55 publications

References 36 publications

Angiotensin-Converting Enzyme Inhibitor Prevents the Worsening of Renal Function in the Late Phase after Percutaneous Coronary Intervention

Angiotensin-Converting Enzyme Inhibitor Prevents the Worsening of Renal Function in the Late Phase after Percutaneous Coronary Intervention

The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients

Coronary Angiography and Contrast-Induced Nephropathy

Contact Info

Product

Resources

About